Suchergebnisse - "Gabellier, Ludovic"

PubPharm (21)

1

Prognostic impact of number of induction courses to attain complete remission in patients with acute myeloid leukemia transplanted with either a matched sibling or human leucocyte antigen 10/10 or 9/10 unrelated donor : An Acute Leukemia Working Party European Society for Blood and Marrow Transplantation study

enthalten in: Cancer | 2024

von Loke, J. | Labopin, M. | Craddock, C. | +20

2

The SUMOylation inhibitor TAK-981 (Subasumstat) triggers IFN-I-dependent activation of Natural Killer cells against Acute Myeloid Leukemias

enthalten in: bioRxiv.org | 2024

von Hallal, R. | De Toledo, M. | Tempé, D. | +10

3

Hypomethylating agent monotherapy in core binding factor acute myeloid leukemia : a French multicentric retrospective study

enthalten in: Annals of hematology | 2024

von Gabellier, L. | Peterlin, P. | Thepot, S. | +16

4

Extreme thrombocytosis with an aggressive evolution harboring a novel variant of calreticulin (CALR) in exon 3

enthalten in: European journal of haematology | 2024

von Bonnet, S. | Carillo, S. | Legrand, B. | +10

5

SUMOylation inhibitor TAK-981 (subasumstat) synergizes with 5-azacytidine in preclinical models of acute myeloid leukemia

enthalten in: Haematologica | 2024

von Gabellier, L. | De Toledo, M. | Chakraborty, M. | +10

6

Clinico-biological features, treatment and prognosis of primary myeloid sarcoma : A French retrospective multi-centric observational study

enthalten in: British journal of haematology | 2023

von Belhadj, M. | Burroni, B. | Kosmider, O. | +16

7

DeSUMOylation of chromatin-bound proteins limits the rapid transcriptional reprogramming induced by daunorubicin in acute myeloid leukemias

enthalten in: Nucleic acids research | 2023

von Boulanger, M. | Aqrouq, M. | Tempé, D. | +19

8

Preventive plasmapheresis for rituximab related flare in cryoglobulinemic vasculitis

enthalten in: Journal of translational autoimmunity | 2023

von Fornero, L. | Kanouni, T. | Tudesq, J. | +7

9

The NADPH oxidase NOX2 is a marker of adverse prognosis involved in chemoresistance of acute myeloid leukemias

enthalten in: Haematologica | 2022

von Paolillo, R. | Boulanger, M. | Gâtel, P. | +13

CommentIn: Haematologica. 2022 Nov 01;107(11):2530-2531. - PMID 35172567

10

Clinical presentation, outcome, and prognostic markers in patients with intravascular large B-cell lymphoma, a lymphoma study association (LYSA) retrospective study

enthalten in: Cancer medicine | 2022

von Bonnet, A. | Bossard, C. | Gabellier, L. | +21